Stock Financial Ratios, Dividends, Split History

AGIO / Agios Pharmaceuticals, Inc. financial ratios include Market Cap, Enterprise Value, Book Value, Quick Ratio, Current Ratio, NCAV, EBITDA, Profit Margin, Operating Margin, Return on Invested Capital (ROIC), Return on Assets (ROA), Return on Equity (ROE), Piotroski F-Score, Altman Z-Score, Beneish M Score and Kaplan-Zingales KZ-Index.

Valuation Metrics
Market Cap ($M)4,955.90
Enterprise Value ($M)4,807.88
Book Value ($M)375.50
Book Value / Share6.55
Price / Book13.08
NCAV ($M)206.37
NCAV / Share3.60
Price / NCAV23.35
Income Statement (mra) ($M)
Net Income-314.67
Balance Sheet (mrq) ($M)
Cash & Equivalents102.72
Cash / Share1.79
Quick Ratio4.69
Current Ratio4.69
Share Statistics
Common Shares Outstanding57,326,741
Preferred Stock Shares Outstanding0
Common Stock Shares Outstanding48,826,153
Scoring Models
Piotroski F-Score0.00
Altman Z ScoreN/A
Beneish M ScoreN/A
Kaplan-Zingales KZ-IndexN/A
Cash Conversion CycleN/A
Management Effectiveness (mra)
Return on Invested Capital (ROIC)-0.84
Return on Assets (ROA)-0.51
Return on Equity (ROE)-0.88
Identifiers and Descriptors
Central Index Key (CIK)1439222
Industry Groups
SIC 2834 - Pharmaceutical Preparations
Related CUSIPS
00847X954 00847X904

Split History

Stock splits are used by Agios Pharmaceuticals, Inc. to keep share prices within reasonable numbers to encourage investment. If the share price of a security gets too high, a company can perform a stock split by issuing all shareholders an extra share, thereby halving the price of an individual share. If the share price gets too low, companies can do reverse splits. This is common when share prices drop below $1.00 and company's become in danger of being delisted. However, because of the cost, stock splits are not a normal business occurrence.

Coming soon

Peers - Pharmaceutical Preparations (2834)

Related Articles

GNCA: Genocea Biosciences Analysis and Research Report

11h - Asif

Overview Genocea Biosciences is a biopharmaceutical company that discovers and develops novel cancer vaccines. The company use its proprietary discovery platform, ATLAS, to recall a patient’s pre-existing CD4+ and CD8+ T cell immune responses to their tumor to identify antigens for inclusion in vaccines that are designed to act through T cell (or cellular) immune responses. The company believe that using ATLAS to identify antigens for inclusion in cancer vaccines could lead to more immunogenic and efficacious cancer vaccines. In September 2017, the company announced a strategic shift to immuno-oncology and a focus on the development of neoantigen cancer vaccines. Currently, all of its research programs and product candidates in active development are at the preclinical stage. The company's most advanced program is its preclinical immuno-oncology program, GEN-009, a neoantigen cancer vaccine. The GEN-009 program uses ATLAS to identify patient neoantigens, or newly formed anti...

AMZN:, Inc Analysis and Research Report

11h - Asif

Overview opened its virtual doors on the World Wide Web in July 1995. The company seek to be Earth’s most customer-centric company. Amazon is guided by four principles: customer obsession rather than competitor focus, passion for invention, commitment to operational excellence, and long-term thinking. In each of its segments, the company serve its primary customer sets, consisting of consumers, sellers, developers, enterprises, and content creators. In addition, the company provide services, such as advertising services and co-branded credit card agreements. Amazon has organized its operations into three segments: North America, International, and Amazon Web Services (“AWS”). These segments reflect the way the Company evaluates its business performance and manages its operations. Additional information on its operating segments and its net sales is contained in Item 8 of Part II, “Financial Statements and Supplementary Data—Note 11—Segment Information.” The compan...

LPCN: Lipocine Inc Analysis and Research Report

2018-04-23 - Asif

Overview Lipocine is a specialty pharmaceutical company focused on applying its oral drug delivery technology for the development of pharmaceutical products in the area of men’s and women’s health. The company's proprietary delivery technologies are designed to improve patient compliance and safety through orally available treatment options. The company's primary development programs are based on oral delivery solutions for poorly bioavailable drugs. Lipocine has a portfolio of proprietary product candidates designed to produce favorable pharmacokinetic (“PK”) characteristics and facilitate lower dosing requirements, bypass first-pass metabolism in certain cases, reduce side effects, and eliminate gastrointestinal interactions that limit bioavailability. The company's lead product candidate, TLANDO™, is an oral testosterone replacement therapy (“TRT”) and is currently under review by the United States Food and Drug Administration (“FDA”) with a Prescription Drug User Fee Act (“...

Related News Stories

Agios' Leukemia Drug Bodes Well for Growth & Strong Pipeline

2018-04-18 zacks
On Apr 17, 2018, we issued an updated report on Agios Pharmaceuticals, Inc. (AGIO - Free Report) , a development-stage biopharmaceutical company focused on development of treatments for cancer and rare genetic metabolic disorders (RGD), a subset of orphan genetic metabolic diseases. (165-1)

The Zacks Analyst Blog Highlights: Agios Pharmaceuticals, BioMarin Pharmaceutical, Vertex Pharmaceuticals and Incyte

2018-04-16 zacks
Chicago, IL – April 16, 2018 – announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include Agios Pharmaceuticals, Inc. (AGIO - Free Report) , BioMarin Pharmaceutical Inc. (BMRN - Free Report) , Vertex Pharmaceuticals, Inc. (VRTX - Free Report) and Incyte Corporation (INCY - Free Report) . (150-0)

Top Analyst Upgrades and Downgrades: Agilent, Alphabet, Amazon, Apple, Citigroup, Facebook, JPMorgan, Mattel, Netflix and More

2018-04-11 247wallst
Stocks surged on Tuesday as trade war fears abated, but tweets about sending missiles at Syrian targets and the Russia implications had futures lower on Wednesday. The bull market is now over nine years old, and it has become more obvious that the trend of buying pullbacks has become much more vulnerable to sellers, volatility and each major news headline. All in all, it is making it more difficult for investors to decide how they want their assets positioned for the rest of 2018 and beyond. (468-3)

Agios Pharmaceuticals Shares Rise on Buyout Speculation

2018-04-10 zacks
Shares of Agios Pharmaceuticals, Inc. (AGIO - Free Report) rallied almost 10% on Apr 9 after speculations were rife that the company might be acquired by other big players in the pharma and biotech industry. This bullish sentiment around the stock among investors was mainly triggered following Novartis’ (NVS - Free Report) yesterday’s announcement that it has inked a deal to acquire the U.S. based clinical stage gene therapy company, AveXis, Inc (AVXS - Free Report) . (34-0)

Rheos Medicines Launches with $60 Million

2018-03-22 biospace
Located in Cambridge, Massachusetts, Rheos Medicines launched with a $60 million Series A financing. The round was backed by Third Rock Ventures. (42-4)

CUSIP: 00847X104